Technical Data
A2300-04
Aprotinin, Bovine (US/North America) (Pancreatic trypsin inhibitor)
250mg
Molecular Biology Storage: -20CShipping: RT
Aprotinin inhibits the activity of several proteolytic enzymes such as chymotrypsin, kallikrein, plasmin and trypsin. It is present in blood and in most tissues, with a high concentration in lung, inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins.
Aprotinin is a natural proteinase inhibitor polypeptide consisting of 58 amino acids arranged in a single polypeptide chain, cross-linked by three disulfide bridges and having a molecular mass of 6512D.

Solubility:
Colorless, clear, complete
Loss on drying:
2.0%
Absorbance:
0.8
Histamine:
0.2ug/3EU
Activity (on dried basis):
5400KIU/mg
Protein impurities of higher molecular mass: Complies
Bacterial endotooxins: None Detected
Abnormal toxicity: Non-toxic

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with ddH2O. Aliquot and store at -20C. Reconstituted product is stable for 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

CAS Number:
9087-70-1
Source: Bovine lung
Form: Supplied as a white powder.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Alston, T.A.: Aprotinin. Int. Anesthesiol. Clin. 42(4): 81-91 (2004). 2. Apeler, H., Peters, J., Schneider, K.H., Dembowsky, K.: Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneimittelforschung 54(8): 483-97 (2004). 3. Khan T.A., Bianchi, C., Feng, J., Stahl, G.: Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 128(4): 602-8 (2004). 4. Gillespie, E.L., Perkerson, K.A., Coleman, C.I.: Possible impact of aprotinin on post-cardiothoracic surgery atrial fibrillation. Conn. Med. 68(7): 439-42 (2004). 5. Levy, J.H.: Safety of aprotinin in heparinized and nonheparinized patients. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 38S-42S (2004). 6. Porte, R.J., Hendriks, H.G.: Blood conservation in liver transplantation: The role of aprotinin. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 31S-37S (2004).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.